Oxcia’s CEO, Ulrika Warpman Berglund, recently presented the company and its proprietary technology platform, O2-DDR, at Investor Target. The presentation highlighted Oxcia’s innovative approach to targeting oxidative stress and DNA Damage Response (DDR) pathways, showcasing the potential of O2-DDR to transform cancer and inflammation treatment.